SCHEMBL12367151

SCHEMBL12367151

O=C1Nc2cccnc2Oc2nnccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 5/20 0.51
CDK2 P24941 4/20 0.51
PLK4 O00444 3/20 0.51
AURKA O14965 3/20 0.51
CHEK2 O96017 3/20 0.51
CSNK1D P48730 3/20 0.51
GSK3A P49840 3/20 0.51
CDK5 Q00535 3/20 0.51
AURKB Q96GD4 3/20 0.51
STK3 Q13188 2/20 0.51
LCK P06239 1/20 0.51
MAPK8 P45983 1/20 0.51
BLK P51451 1/20 0.51
CYP1A2 P05177 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ALDH1A1 P00352 2/20 0.40
ALOX15 P16050 1/20 0.40
MAPK10 P53779 1/20 0.40
HSD17B10 Q99714 1/20 0.40
RAB9A P51151 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL477913 0.81 CDK2 (0.56) GSK3BCDK2PLK4AURKACHEK2
SCHEMBL12367149 0.78 GSK3B (0.43) GSK3BCDK2PLK4AURKACHEK2
SCHEMBL7336729 0.76 CYP1A2 (0.55) GSK3BCDK2PLK4AURKACHEK2
SCHEMBL1367080 0.73 CYP1A2 (0.55) GSK3BCDK2PLK4AURKACHEK2
SCHEMBL12367153 0.72 CDK2 (0.43) GSK3BCDK2PLK4AURKACHEK2
SCHEMBL12367148 0.72 PLK4 (0.43) GSK3BCDK2PLK4AURKACHEK2
SCHEMBL12367150 0.72 CDK2 (0.43) GSK3BCDK2PLK4AURKACHEK2
SCHEMBL9180628 0.70 CHEK1 (0.43) CYP1A2SMN1; SMN2MAPTCHEK1
SCHEMBL2265343 0.68 GSK3B (1.00) GSK3BCDK2PLK4AURKACHEK2
SCHEMBL12367152 0.68 PLK4 (0.35) GSK3BCDK2PLK4AURKACHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994160-B2 Pyridazine compounds as glycogen synthase kinase 3 inhibitors ABBOTT GMBH & CO. KG (DE) 2011-08-09 US disclosed
US-20090325937-A1 Pyridazine Compounds as Glycogen Synthase Kinase 3 Inhibitors ABBOTT GMBH & CO. KG (DE) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325937-A1 Pyridazine Compounds as Glycogen Synthase Kinase 3 Inhibitors GSK3B, GSK3A, GYS2 GSK3B 1/4885CDK2 32/4885PLK4 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.